

Hepatitis C - Pipeline Insight, 2021

<https://marketpublishers.com/r/H63F6997BD73EN.html>

Date: July 2021

Pages: 100

Price: US\$ 2,000.00 (Single User License)

ID: H63F6997BD73EN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Hepatitis C - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hepatitis C Understanding

Hepatitis C: Overview

Hepatitis C is a liver infection caused by the hepatitis C virus. Hepatitis C can range from a mild illness lasting a few weeks to a serious, long-term illness. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood. Hepatitis C is often described as "acute," meaning a new infection, or "chronic," meaning long-term infection. Chronic hepatitis C can be a serious disease resulting in long-term health problems, including liver damage, liver failure, cirrhosis, liver cancer, and even death. Symptoms may include fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, grey-colored faeces,

joint pain and jaundice (yellowing of skin and the whites of the eyes). Treatments for hepatitis C includes antivirals, like medications called direct-acting antivirals (DAAs) work to fully remove the hepatitis C virus from the body while helping prevent liver damage.

'Hepatitis C - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis C pipeline landscape is provided which includes the disease overview and Hepatitis C treatment guidelines. The assessment part of the report embraces, in depth Hepatitis C commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis C collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C.

Hepatitis C Emerging Drugs Chapters

This segment of the Hepatitis C report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis C Emerging Drugs

TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic hepatitis C virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.

SH229: Nanjing Sanhome Pharmaceutical

SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic hepatitis C virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of hepatitis C virus infection.

Further product details are provided in the report.....

Hepatitis C: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis C drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hepatitis C

There are approx. 20+ key companies which are developing the therapies for Hepatitis C. The companies which have their Hepatitis C drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hepatitis C pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis C: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C drugs.

Hepatitis C Report Insights

- Hepatitis C Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Hepatitis C Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Hepatitis C drugs?

How many Hepatitis C drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hepatitis C and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Dongguan HEC TaiGen Biopharmaceuticals

Nanjing Sanhome Pharmaceutical

PharmaEssentia

HEC Pharm

Atea Pharmaceuticals

AllaChem

HepC

Sunshine Lake Pharma

GeneCure Biotechnologies

Therapure Innovations

Adaptimmune

Orgenesis

Dekk-Tec

Key Products

TG-2349

SH229

Ropeginterferonum alfa-2b

Yimitasvir

AT 527

AV4025

HC-001

HEC 74647PA

Prophylactic HCV vaccine

TBI-301

Research program: T-cell therapies

Research programme: antiviral vaccines

IFN alpha CS(g)

Contents

- Introduction
- Executive Summary
- Hepatitis C: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- AT 527: Atea Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- HEC 74647PA: Sunshine Lake Pharma
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

Prophylactic HCV vaccine: GeneCure Biotechnologies

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Hepatitis C Key Companies

Hepatitis C Key Products

Hepatitis C- Unmet Needs

Hepatitis C- Market Drivers and Barriers

Hepatitis C- Future Perspectives and Conclusion

Hepatitis C Analyst Views

Hepatitis C Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Hepatitis C
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hepatitis C
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hepatitis C - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H63F6997BD73EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H63F6997BD73EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970